MedPath

Renin Angiotensin SyStem blockade: diabetes nephropathy

Not Applicable
Completed
Conditions
Diabetic Nephropathy (DN)
Nutritional, Metabolic, Endocrine
Registration Number
ISRCTN65752530
Lead Sponsor
Canadian Institutes of Health Research (CIHR) (Canada)
Brief Summary

2011 Results article in https://doi.org/10.2337/dc11-0476 (added 27/10/2021)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
223
Inclusion Criteria

1. Patients with type one diabetes
2. Normal Glomerular Filtration Rate (GFR) and Blood Pressure (BP)
3. Normoalbuminuria
4. Either sex, 18 to 64 years of age

Exclusion Criteria

1. Type one Diabetes Mellitus longer then 20 years
2. BP more than 135/85 mmHg
3. GFR less than 90 ml/min
4. Microalbuminuria
5. Soiltary kidney
6. Other chronic disease
7. Pregnancy or planning pregnancy within two years of randomisation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome is to determine, in Type one diabetes without clinical evidence of diabetic nephropathy, if inhibition of the renin-angiotensin system activity can prevent or retard the rate of development of the histologic lesions associated with diabetic nephropathy.
Secondary Outcome Measures
NameTimeMethod
<br> 1. Retinopathy<br> 2. Microalbuminuria<br> 3. Blood pressure<br> 4. GFR<br> 5. Creatinine<br>
© Copyright 2025. All Rights Reserved by MedPath